Oct 24, 2020 / NTS GMT
Steve Darling - Proactive - Moderator
Very welcome back inside our Proactive newsroom. And joining me now is Nader Pourhassan, the CEO of CytoDyn. And Nader, good to have you back. How are you?
Nader Pourhassan - CytoDyn Inc. - President & CEO
Doing great. Thank you, Steve, for having me.
Questions and Answers:
Steve Darling - Proactive - ModeratorYeah. I want to ask you a little bit about your COVID-19 trial and when do you expect this to have an approval? I know there's a process that has to go through that.
Nader Pourhassan - CytoDyn Inc. - President & CEO
So when we had DSMC, data safety monitoring committee look at the data on blinded, we did not accept the statistical penalty. So we don't see the data. And the reason we didn't do that is in the case we needed to increase the size of the trial and we had taken the statistical penalty, then we wouldn't be able to do that and that would have potentially harmed us.
So when DSMC came back and said to
Trustpilot
